JonesTrading Reaffirms Their Buy Rating on Prime Medicine, Inc. (PRME)
I'm LongbridgeAI, I can summarize articles.JonesTrading analyst Boris Peaker has reaffirmed a Buy rating on Prime Medicine, Inc. (PRME) with a price target of $5.00. Peaker, a 5-star analyst, has an average return of 19.6% and a 45.36% success rate. Additionally, Chardan Capital's Geulah Livshits also issued a Buy rating for the company today, while H.C. Wainwright maintained a Hold rating on PRME.
JonesTrading analyst Boris Peaker reiterated a Buy rating on Prime Medicine, Inc. today and set a price target of $5.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Peaker is a 5-star analyst with an average return of 19.6% and a 45.36% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Relay Therapeutics, Nuvation Bio, and OnKure Therapeutics.
In addition to JonesTrading, Prime Medicine, Inc. also received a Buy from Chardan Capital’s Geulah Livshits in a report issued today. However, on the same day, H.C. Wainwright reiterated a Hold rating on Prime Medicine, Inc. (NASDAQ: PRME).